Self-reported adverse events after 2 doses of COVID-19 vaccine in Korea
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
OBJECTIVES: In Korea, a national coronavirus disease 2019 (COVID-19) vaccination program was implemented, including 4 vaccines against COVID-19. A text messaging-based survey, in addition to a passive adverse event reporting system, was launched to quickly report unusual symptoms post-vaccination. This study compared the frequency of adverse events after COVID-19 vaccination based on the vaccine type and the type of 2-dose regimen (homologous or heterologous). METHODS: Self-reported adverse events were collected through a text-message survey for 7 days after each vaccination. This study included 50,950 vaccine recipients who responded to the survey at least once. Informed consent to receive surveys via text was obtained from the vaccine recipients on the date of first vaccination. RESULTS: The recipients of mRNA vaccines reported local and systemic reactions 1.6 times to 2.8 times more frequently after dose 2 than after dose 1 (p<0.001), whereas ChAdOx1-S recipients reported significantly fewer local and systemic reactions after dose 2 than after dose 1 (p<0.001). Local and systemic reactions were approximately 2 times and 4 times more frequent for heterologous vaccination than for BNT162b2/BNT162b2 and ChAdOx1-S/ChAdOx1-S regimens, respectively. Young individuals, female, and those receiving heterologous vaccine regimens including ChAdOx1-S/BNT162b2 vaccines reported more adverse events than older participants, male, and those with homologous vaccine regimens. CONCLUSIONS: Although a heterologous regimen, youth, and female sex were associated with a higher risk of adverse reactions after COVID-19 vaccination, no critical issues were noted. Active consideration of heterologous schedules based on the evidence of efficacy and safety appears desirable.
Abstract
OBJECTIVES: In Korea, a national coronavirus disease 2019 (COVID-19) vaccination program was implemented, including 4 vaccines against COVID-19. A text messaging-based survey, in addition to a passive adverse event reporting system, was launched to quickly report unusual symptoms post-vaccination. This study compared the frequency of adverse events after COVID-19 vaccination based on the vaccine type and the type of 2-dose regimen (homologous or heterologous). METHODS: Self-reported adverse events were collected through a text-message survey for 7 days after each vaccination. This study included 50,950 vaccine recipients who responded to the survey at least once. Informed consent to receive surveys via text was obtained from the vaccine recipients on the date of first vaccination. RESULTS: The recipients of mRNA vaccines reported local and systemic reactions 1.6 times to 2.8 times more frequently after dose 2 than after dose 1 (p<0.001), whereas ChAdOx1-S recipients reported significantly fewer local and systemic reactions after dose 2 than after dose 1 (p<0.001). Local and systemic reactions were approximately 2 times and 4 times more frequent for heterologous vaccination than for BNT162b2/BNT162b2 and ChAdOx1-S/ChAdOx1-S regimens, respectively. Young individuals, female, and those receiving heterologous vaccine regimens including ChAdOx1-S/BNT162b2 vaccines reported more adverse events than older participants, male, and those with homologous vaccine regimens. CONCLUSIONS: Although a heterologous regimen, youth, and female sex were associated with a higher risk of adverse reactions after COVID-19 vaccination, no critical issues were noted. Active consideration of heterologous schedules based on the evidence of efficacy and safety appears desirable.
참고문헌 (29)
- "WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020"[URL]
- "Annual report for drug approval" (2021)[URL]
- "Approval information for COVID-19 vaccine"[URL]
- "COVID-19 vaccination plan" (2021)[URL]
- "Update on COVID19 vaccination plan 2021" (2021)[URL]
- Kwon SL, "COVID-19 vaccination program in South Korea : a long journey toward a new normal", Health Policy Technol, 11, pp.100601~ (2022)
- "COVID-19 vaccination guideline 2022"[URL]
- Chapin-Bardales J, "Reactogenicity following receipt of mRNA-based COVID-19 vaccines", JAMA, 325, pp.2201~2202 (2021)
- "COVID-19 vaccine monitoring"[URL]
- 황인섭, "COVID-19 vaccine safety monitoring in Republic of Korea from February 26, 2021 to October 31, 2021", Osong Public Health and Research Perspectives, 12(6), pp.396~402 (2021), 질병관리청[DOI]
- Hause AM, "Safety monitoring of an additional dose of COVID-19 vaccine-United States, August 12-September 19, 2021", MMWR Morb Mortal Wkly Rep, 70, pp.1379~1384 (2021)
- Kamal D, "Adverse events following ChAdOx1 nCoV-19 vaccine(COVISHIELD)amongst health care workers : a prospective observational study", Med J Armed Forces India, 77(Suppl 2), pp.S283~S288 (2021)
- Dziedzic A, "Self-reported adverse events of COVID-19 vaccines in Polish healthcare workers and medical students. Cross-sectional study and pooled analysis of CoVaST project results in Central Europe", J Clin Med, 10, pp.5338~ (2021)
- Cheng Y, "Self-reported adverse events among Chinese healthcare workers immunized with COVID-19 vaccines composed of inactivated SARS-CoV-2", Hum Vaccin Immunother, 18, pp.2064134~ (2022)
- Kadali RA, "Side effects of BNT162b2 mRNA COVID-19 vac-cine : a randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers", Int J Infect Dis, 106, pp.376~381 (2021)
- Beatty AL, "Analysis of COVID-19 vaccine type and adverse effects following vaccination", JAMA Netw Open, 4, pp.e2140364~ (2021)
- Xiong X, "Age and gender disparities in adverse events following COVID-19 vaccination: real-world evidence based on big data for risk management", Front Med(Lausanne), 8, pp.700014~ (2021)
- Green MS, "Gender differences in adverse events following the Pfizer-BioNTech COVID-19 vaccine", Vaccines(Basel), 10, pp.233~ (2022)
- "Weekly safety monitoring reports, in weekly safety monitoring reports" (2021)[URL]
- Ledford H, "Could mixing COVID vaccines boost immune response?", Nature, 590, pp.375~376 (2021)
- Hillus D, "Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2 : a prospective cohort study", Lancet Respir Med, 9, pp.1255~1265 (2021)
- "Update on COVID-19 and COVID-19 vaccination" (2021)[URL]
- Duarte-Salles T, "Heterologous vaccine regimens against COVID-19", Lancet, 398, pp.94~95 (2021)
- Andersson NW, "Safety of heterolo-gous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines : na-tionwide cohort study", BMJ, 378, pp.e070483~ (2022)
- "Updated action plan for COVID-19 vaccination" (2021)[URL]
- Powell AA, "Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England", Euro Surveill, 26, pp.2100634~ (2021)
- Planas D, "Sensitivity of infec-tious SARS-CoV-2 B. 1. 1. 7 and B. 1. 351 variants to neutralizing antibodies", Nat Med, 27, pp.917~924 (2021)
- Barros-Martins J, "Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19", BNT162b2 vaccination, 2021, pp.27, 1525~1529
- Shaw RH, "Heterologous prime-boost COVID-19 vaccination : initial reactogenicity data", Lancet, 397, pp.2043~2046 (2021)